Phase 3 N=154 Long Term Administration Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score — -2.2; -2.7; -4.1; -4.6 FCS score — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=445 A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Pulmonary Hypertension
Primary: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 — 29.6; 31.1; -5.6 Meters — p=<0.0001
Phase 2 N=22 Clonidine Versus Adenosine to Treat Neuropathic Pain
Pain
Primary: Number Meeting Success Criterion — 10; 5; 0 participants meeting success criterion — p=>0.05
N/A N=141 Post-operative Sore Throat as Determined by Endotracheal Tube Inflation Technique
Post Operative Sore Throat · Dysphagia · Hoarseness
Primary: Incidence of Tracheopharyngeal Symptoms — 53; 49 participants
Phase 2 N=84 Study of Medical Treatment for Methamphetamine Addiction
Methamphetamine · Amphetamine Dependence · Pharmacogenetics
Primary: Treatment Effectiveness Score — 16.1; 10.6 urine drug screens
N/A N=1,291 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
Arthritis, Psoriatic · Psoriasis · Skin Diseases, Papulosquamous
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 38.1; 6.0 percentage of participants
Phase 4 N=908 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
Pneumococcal Vaccines
Primary: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series — 1.64; 1.99; 1.48; 2.07 microgram…
N/A N=220 Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting
Quadrivalent HPV Vaccine · Human Papillomavirus Vaccine
Primary: Immunogenicity After Dose 3 — 1063; 794; 1961; 1043 mM units/ml
Phase 2 N=5 CNTF Implants for CNGB3 Achromatopsia
Eye Disease · Achromatopsia
Primary: Number of Adverse Events at Six Months Post-Implantation — 10 Adverse Events
N/A N=105 Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Efficacy of the New CPRV
Primary: Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT) — 0; 0; 0 International unit per ml
Phase 2 N=96 Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
Gastric Cancer
Primary: Response Rate — 28.9; 26.1 percentage of participants
Phase 3 N=389 Study of Pyridoxine for Hand-Foot Syndrome
Hand-foot Syndrome
Primary: Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome — 70000; 70000 miligram per square meter
Phase 3 N=684 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet…
Phase 4 N=70 Greater Occipital Nerve Block for Migraine Prophylaxis
Migraine Headache
Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…
N/A N=16 Effects of Wearing a Powered Ankle-Foot Prosthesis on Amputee Walking
Traumatic Amputation of Lower Extremity
Primary: Metabolic Cost of Transport — 4.76; 4.57; 4.68; 4.11 J/Nm